heparitin-sulfate has been researched along with Mitral-Valve-Insufficiency* in 2 studies
1 review(s) available for heparitin-sulfate and Mitral-Valve-Insufficiency
| Article | Year |
|---|---|
[Use of Organon, a synthetic heparinoid, in two cardiopulmonary bypass procedures in the same patient sensitive to heparin].
We report the case of a patient who underwent two cardiopulmonary bypass (CPB) procedures with Orgaran because of heparin-induced thrombocytopenia. A 38 years-old man with ischemic mitral insufficiency was operated for coronary artery bypass and valvular replacement. The CPB was carried out with heparin. Heparin-induced thrombocytopenia occured and was proven immunologically. Two months later, a new valvular replacement was performed because of paravalvular leak due to endocarditis. The Orgaran-CPB protocol was as follows: 5,000 units before cardiopulmonary bypass, 5,000 units in the priming volume, anti-Xa level between 0.9 and 1.1 units/mL, with injection of 1,500 units if necessary, no administration of protamine. One month later, a new valvular replacement was necessary and performed with the same protocol using Orgaran. No bleeding or thrombotic complication occurred. Orgaran is a safe and reliable anti-thrombotic substitute if anti-Xa activity is closely monitored. Topics: Adult; Anticoagulants; Cardiopulmonary Bypass; Chondroitin Sulfates; Coronary Artery Bypass; Dermatan Sulfate; Endocarditis; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Heparin; Heparin Antagonists; Heparitin Sulfate; Humans; Male; Mitral Valve Insufficiency; Prosthesis Failure; Protamines; Reoperation; Thrombocytopenia; Treatment Outcome | 2001 |
1 other study(ies) available for heparitin-sulfate and Mitral-Valve-Insufficiency
| Article | Year |
|---|---|
[Extracorporeal circulation with danaparoid sodium for valve replacement in thrombocytopenia induced by type II heparin].
A type II heparin-induced thrombocytopenia (HIT) was diagnosed in a 64-year-old woman at day 20 of intravenous unfractionated heparin (UFH) therapy, given after myocardial infarction treated by angioplasty and intracoronary stent. The infarction was complicated by a mitral insufficiency that led to a mitral valve replacement. Cardiopulmonary bypass was successfully performed with sodium danaparoid (Orgaran), as an alternative to UFH, without thrombotic or haemorrhagic complications and the follow-up was uneventful. Topics: Anticoagulants; Chondroitin Sulfates; Dermatan Sulfate; Drug Combinations; Extracorporeal Circulation; Female; Heart Valve Prosthesis; Heparin; Heparitin Sulfate; Humans; Middle Aged; Mitral Valve Insufficiency; Thrombocytopenia | 2001 |